Cadila Healthcare announced that the USFDA inspected the Pharmaceutical Technology Centre (PTC), the company's state-ofthe-art R&D facility located at Ahmedabad, dedicated to new product development of various niche dosage forms including solid oral, parenteral, pulmonary, oncology, ointment & creams and transdermal, from 18 March to 22 March 2019.

At the end of the inspection, no observations (483) have been issued.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)